Larger tumors and younger age are significantly associated with an increased risk of brain metastasis in patients with renal cell carcinoma, according to investigators.
AKI promotes the development of papillary renal cell carcinoma from single progenitors.
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
In a study, patients with kidney failure due to urinary tract cancers had an increased mortality risk and decreased access to kidney transplantation if they had active malignancy at the start of dialysis.
Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.
Researchers assessed changes in the estimated glomerular filtration rate among patients with gout with moderate renal impairment, using a treat-to-target approach for gout.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.